Introduction: Neonatal sepsis remains a serious and potentially fatal illness. Intrapartum antibiotic prophylaxis (IAP) prevents group B streptococcal (GBS) early-onset sepsis. The optimal duration of IAP (adequate IAP) to reduce vertical transmission of GBS has been debated. Understanding the mechanism of action of IAP may help in minimizing neonatal evaluation and unnecessary antibiotic use. Areas covered: In recent years, several studies on pharmacokinetics and clinical use of IAP have been published. Although penicillin and ampicillin are the most preferred antibiotics, the clinical efficacy of non-beta-lactam antibiotics, including clindamycin and vancomycin, used in cases of penicillin anaphylaxis-associated allergy, remains debatable. This is a narrative review of the literature regarding the impact of ‘inadequate’ IAP on the clinical management of women and newborns. Expert opinion: Recent evidence suggests that ‘inadequate’ IAP with beta-lactams is more effective in preventing vertical transmission of GBS than previously thought. Newborns exposed to intrapartum beta-lactams and who are asymptomatic at birth are likely uninfected, irrespective of IAP duration before delivery. Hence, we may abandon the concept of ‘inadequate’ IAP with beta-lactams in early-onset GBS sepsis, relying primarily on clinical signs observed at birth for managing IAP-exposed neonates.

Intrapartum beta-lactam antibiotics for preventing group B streptococcal early-onset disease: can we abandon the concept of ‘inadequate’ intrapartum antibiotic prophylaxis? / Berardi, A.; Spada, C.; Vaccina, E.; Boncompagni, A.; Bedetti, L.; Lucaccioni, L.. - In: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. - ISSN 1478-7210. - 18:1(2020), pp. 37-46. [10.1080/14787210.2020.1697233]

Intrapartum beta-lactam antibiotics for preventing group B streptococcal early-onset disease: can we abandon the concept of ‘inadequate’ intrapartum antibiotic prophylaxis?

Berardi A.;Vaccina E.;Boncompagni A.;Bedetti L.;Lucaccioni L.
2020

Abstract

Introduction: Neonatal sepsis remains a serious and potentially fatal illness. Intrapartum antibiotic prophylaxis (IAP) prevents group B streptococcal (GBS) early-onset sepsis. The optimal duration of IAP (adequate IAP) to reduce vertical transmission of GBS has been debated. Understanding the mechanism of action of IAP may help in minimizing neonatal evaluation and unnecessary antibiotic use. Areas covered: In recent years, several studies on pharmacokinetics and clinical use of IAP have been published. Although penicillin and ampicillin are the most preferred antibiotics, the clinical efficacy of non-beta-lactam antibiotics, including clindamycin and vancomycin, used in cases of penicillin anaphylaxis-associated allergy, remains debatable. This is a narrative review of the literature regarding the impact of ‘inadequate’ IAP on the clinical management of women and newborns. Expert opinion: Recent evidence suggests that ‘inadequate’ IAP with beta-lactams is more effective in preventing vertical transmission of GBS than previously thought. Newborns exposed to intrapartum beta-lactams and who are asymptomatic at birth are likely uninfected, irrespective of IAP duration before delivery. Hence, we may abandon the concept of ‘inadequate’ IAP with beta-lactams in early-onset GBS sepsis, relying primarily on clinical signs observed at birth for managing IAP-exposed neonates.
2020
6-dic-2019
18
1
37
46
Intrapartum beta-lactam antibiotics for preventing group B streptococcal early-onset disease: can we abandon the concept of ‘inadequate’ intrapartum antibiotic prophylaxis? / Berardi, A.; Spada, C.; Vaccina, E.; Boncompagni, A.; Bedetti, L.; Lucaccioni, L.. - In: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. - ISSN 1478-7210. - 18:1(2020), pp. 37-46. [10.1080/14787210.2020.1697233]
Berardi, A.; Spada, C.; Vaccina, E.; Boncompagni, A.; Bedetti, L.; Lucaccioni, L.
File in questo prodotto:
File Dimensione Formato  
Beta Lactam antibiotics for preventing EOD (Berardi et al, Exp Rev Ant Ther 2019).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 802.76 kB
Formato Adobe PDF
802.76 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1186994
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact